FDA orders vision loss warning on all GLP-1 drug labels

The US Food and Drug Administration said on Monday it is requiring every GLP-1 drug to carry label information about a potential increased risk of NAION, a rare eye condition that can cause permanent vision loss.

Why it matters: The requirement covers the whole class behind Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, the industry's highest revenue drug franchise, and follows the European regulator's earlier finding on semaglutide.

Data as of US Food and Drug Administration drug safety communication of November 9, 2026, read in full; every figure and the label requirement are the agency's own. Investing.com's report of November 9, 2026, read in full via the estate browser route, corroborates the requirement. Developing item.

The FDA said it is requiring application holders to add information about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of the labelling of all GLP-1 receptor agonists, after a comprehensive evaluation of clinical trial data, animal data and postmarketing data. Its meta-analysis of 126 trials covering 134,253 patients found 6.4 NAION events per 100,000 patient-years on GLP-1 drugs against 3.8 on comparators, and its Sentinel cohort study in adults with type 2 diabetes found a 43 percent higher risk than DPP-4 inhibitors and no statistically significant difference against SGLT-2 inhibitors. The agency said NAION cases have been reported for all currently marketed GLP-1 products, that its review of animal data found no mechanism for the risk, and that the condition is a common cause of sudden, painless vision loss that can leave permanent impairment.

FDA orders vision loss warning on all GLP-1 drug labels

Sources